Sinopharm Group (1099) Stock Price, Fundamentals & Analysis

What 1099 does

Sinopharm Group (1099) is a stock listed on the Hong Kong Stock Exchange in the Healthcare sector, specifically the Medical Distribution industry. The company, headquartered in Shanghai, China, and employing 90,447 people, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. It operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics, and also offers distribution, logistics, and other value-added services for domestic and international manufacturers and suppliers. The Medical Devices Distribution segment distributes medical devices and provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores, while the Other Business segment handles laboratory supplies, chemical reagents, and the production and sale of pharmaceutical products. Sinopharm Group operates in a competitive space alongside peers such as WuXi Biologics (2269), CSPC Pharmaceutical Group (1093), and Sino Biopharm (1177).

Key numbers explained

• The current price is 14.88 HKD, down 0.2% today. The 52-week range is 14.6 to 22.34, and the price change over the last 52 weeks is -18.9%.
• The trailing P/E ratio of 5.6 and the forward P/E ratio of 5 compare the share price to the company's earnings per share, with the forward version using expected future earnings.
• The dividend yield of 5.31% shows the annual dividend as a percentage of the current share price. The ex-dividend date is Jun 23, 2026, and 30% of earnings are paid out as dividends.
• The beta of 0.44 suggests the stock has historically been less volatile than the overall market.
• The price-to-book ratio of 0.47 compares the share price to the company's book value per share, with a figure below 1 potentially indicating the market values the company below its accounting net assets.
• The debt-to-equity ratio of 59.6% indicates the proportion of debt used to finance the company relative to shareholder equity.
• The return on equity of 8% measures how effectively the company generates profits from shareholders' equity.
• The profit margin of 1.2% and operating margin of 3% show how much of each revenue dollar remains as profit after expenses.

What to watch

Sinopharm Group's performance is tied to the broader Healthcare sector and the Medical Distribution industry, which can be influenced by government healthcare policies, drug pricing regulations, and public health demand in China. Investors often monitor the company alongside peers like Alibaba Health (0241), WuXi AppTec (2359), and JD Health (6618) to understand sector trends. The company's revenue growth, reported at -1.6% year over year for trailing 12 months, and its profit margin of 1.2% are key indicators of operational efficiency. The next earnings date is Oct 20, 2026, which is a common catalyst for price movement. As a component of the Hong Kong Stock Exchange, the stock is also subject to broader market dynamics tracked by indices like the Hang Seng.